Introduction
============

Numerous epidemiologic studies have examined the association between nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer, with equivocal results. Most, but not all, case--control studies have found relative risk reductions from 20% to 40% \[[@B1]-[@B3]\] (reviewed in \[[@B4]-[@B7]\]). Results from prospective studies have been less consistent, with eight reports finding no association \[[@B8]-[@B15]\], two studies observing an increased risk \[[@B16],[@B17]\], one study reporting a U-shaped association \[[@B18]\], and six studies demonstrating a reduced risk \[[@B19]-[@B24]\]. In the Women\'s Health Study randomized clinical trial, alternate-day use of low-dose aspirin for an average of 10 years did not reduce the incidence of breast cancer \[[@B25]\]. Given the potential public health impact of NSAIDs as chemopreventive agents for breast cancer, an increased understanding of the relationship between NSAIDs and breast cancer is needed.

A protective role of NSAIDs in breast carcinogenesis is biologically plausible. *In vitro*and animal studies have consistently shown that NSAIDs inhibit cyclooxygenase (COX)-1 and COX-2, which cyclize and oxygenate arachidonic acid, eventually producing prostaglandins \[[@B26]\]. While inhibiting COX-1 reduces both platelet aggregation and gastric cytoprotection \[[@B27]\], inactivating COX-2 may interrupt the carcinogenic process in the breast via multiple pathways -- including inhibition of angiogenesis, promotion of apoptosis, and suppression of estrogen synthesis via decreased aromatase activity \[[@B28]\].

Since aspirin and nonaspirin NSAIDs have different biologic effects (aspirin permanently inactivates COX-2 \[[@B29]\]), separate evaluation is needed with respect to breast cancer risk. Interpretation of prior epidemiologic studies is complicated by incomplete attention to NSAID type \[[@B5]\]. Furthermore, the studies that have examined the effect of NSAIDs on breast cancer risk by tumor characteristics, such as hormone receptor (HR) status \[[@B3],[@B13],[@B16]-[@B18],[@B23],[@B24],[@B30],[@B31]\] and stage at diagnosis \[[@B21],[@B30],[@B32]\], also present conflicting results. The relatively few studies that have tested for effect modification by participant characteristics (for example, body mass index, menopausal hormone therapy use, or smoking status) have produced inconclusive findings \[[@B13],[@B17],[@B18],[@B20],[@B22],[@B24],[@B25],[@B32],[@B33]\]. The large cohort of women participating in the prospective National Institutes of Health (NIH)--AARP Diet and Health Study allowed us to evaluate these questions.

Materials and methods
=====================

Study population
----------------

The NIH--AARP Diet and Health Study design and methodology have been described in detail \[[@B34]\]. Briefly, the NIH--AARP Study is a prospective cohort study of diet, health-related behaviors and cancer.

The study was initiated in 1995 and 1996 when a questionnaire was mailed to 3.5 million members of the AARP (formerly known as the American Association of Retired Persons) aged 50 to 71 years, who resided in one of six states (California, Florida, Pennsylvania, New Jersey, North Carolina, and Louisiana) or two metropolitan areas (Atlanta, Georgia and Detroit, Michigan) that have large AARP membership, large minority populations, and high-quality cancer registries. The questionnaire captured diet history, demographic characteristics, reproductive history, menopausal status, and family history of cancer. Of the 617,119 men and women (17.6%) who returned the questionnaire, 567,169 satisfactorily completed it.

In 1996 and 1997 a second questionnaire was sent to collect additional information on family history of cancer, anthropometry, and use of menopausal hormone therapy (HT) and other medications, including NSAIDs. A total of 337,074 men and women completed this questionnaire.

After excluding individuals who died or moved out of the cancer registry ascertainment area before their second questionnaire was received and scanned (*n* = 2,166), excluding proxy respondents to the baseline (*n* = 6,959) or second (*n* = 3,424) questionnaires, and excluding 188,117 men, the study population included 136,408 potentially eligible women

The study was approved by the Special Studies Institutional Review Board of the US National Cancer Institute.

Assessment of nonsteroidal anti-inflammatory drug exposure and covariates
-------------------------------------------------------------------------

The second questionnaire asked whether aspirin products (generic aspirin, Bayer, Bufferin, Anacin, Ecotrin, or Excedrin) and nonaspirin NSAIDs (generic ibuprofen, Advil, Nuprin, Motrin, Naprosyn, and so on) had been used in the past 12 months. As acetaminophen is an analgesic with weak anti-inflammatory activity \[[@B35]\], participants were instructed not to include \'Tylenol, acetaminophen, or any other pain relievers\' in nonaspirin NSAIDs. Aspirin or nonaspirin NSAID users were asked to indicate their frequency of usual use: fewer than 2 times per month, 2 to 3 times per month, 1 to 2 times per week, 3 to 4 times per week, 5 to 6 times per week, 1 time per day, or 2 or more times per day -- which we collapsed to categories of nonuse, \<1/week, 1 to 6/week, and ≥1/day. The dose, duration, and indication for use were not collected. In the current report, \'any NSAID\' combines the use of aspirin and nonaspirin NSAIDs.

While the demographic characteristics, lifestyle, and reproductive history were largely obtained through the first questionnaire, the second questionnaire ascertained a self-reported history of hypertension, mammogram screening, and vigorous physical activity. Menopausal hormone therapy use and history of breast cancer in a first-degree relative were derived from information collected on both the first and second questionnaires.

Cohort follow-up
----------------

Cohort members were followed annually for mailing address changes and vital status. Address changes were identified through linkage to the US Postal Service\'s National Change of Address database, through US Postal Service updates received with undeliverable mail, through use of other address change update services, and through participants\' notifications. Vital status was updated through linkage to the Social Security Administration Death Master File and was verified by the National Death Index.

Ascertainment of breast cancer
------------------------------

Incident *in situ*breast cancers and invasive breast cancers were initially identified through probabilistic linkage to eight state cancer registries using first and last name, address, sex, date of birth, and Social Security Number from the baseline questionnaire. The cancer registry ascertainment area was recently expanded to include three additional states (Texas, Arizona, and Nevada) to capture cancer occurring among participants who moved to those states during follow-up. Each registry has been certified by the North American Association of Central Cancer Registries for meeting the highest standards of data quality.

Breast cancer estrogen receptor (ER) status was coded as described in the American Joint Committee on Cancer\'s Collaborative Staging Site-Specific Factors Manual, with a threshold of \>10 fmol cytosol protein per milligram for a positive tumor; however, the ER status was not reported by the Florida, Michigan, and Pennsylvania cancer registries. Histology was defined using the International Classification of Diseases for Oncology codes, third edition \[[@B36]\]. A previous validation study in this cohort estimated that registry linkage validly identified approximately 90% of all incident cancers \[[@B37]\]. The date of death for fatal cancers was identified through linkage to the National Death Index.

Analytic sample
---------------

Because information regarding NSAID use was not collected on the baseline questionnaire, we limited analyses to the 136,408 women who completed the second questionnaire. We excluded 9,022 women who reported a personal cancer history other than nonmelanoma skin cancer on either questionnaire (including 942 breast cancers), 1,259 women who were missing information on NSAID use (including 52 breast cancers), and three women with no follow-up. Thus, 126,124 women were included in the present analyses.

Through 31 December 2003, 4,501 women developed breast cancer (781 *in situ*, 3,703 invasive, and 17 missing stage). Among the 2,282 invasive breast cancer cases from states that collected the ER status, 1,439 were coded as ER-positive and 280 as ER-negative (the ER status was unavailable for the remaining 563 invasive cases). There were no substantial risk factor differences between women from states where ER information was available and states where it was unavailable. The majority of invasive breast cancers were ductal carcinomas (*n* = 2,409), followed by lobular (*n* = 400), mixed (*n* = 310), and other (*n* = 584) histologic types.

Statistical analysis
--------------------

Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals (CIs) for breast cancer associated with NSAID use; age was the time scale \[[@B38]\], and ties were handled by enumeration \[[@B39]\]. Follow-up began at the age at which the second questionnaire was received and scanned, and continued through the earliest of the following dates: participant diagnosed with breast cancer, moved out of her registry catchment area, died from any cause, or 31 December 2003. To test the proportional hazards assumption, we generated time-dependent covariates by including interactions of each predictor with the natural log of age (the time metric); probability values for all time-dependent covariates were \>0.05, consistent with hazards that are proportional.

Multivariate models were used to control for age at entry (years), race/ethnicity (white versus other/unknown), age at first birth (nulliparous, \<20 years, 20 to 24 years, 25 to 29 years, ≥30 years, or unknown), HT use (never used, estrogen only, estrogen--progestin, or other/unknown), number of breast biopsies (0, 1, 2, ≥3, or unknown), alcoholic drinks per day (0, \<1, 1 to 3, ≥3, or unknown), history of hypertension (no, yes, or unknown), and family history of breast cancer in a first-degree relative (no, yes, or unknown). Models examining frequency of aspirin use and breast cancer risk also included terms for frequency of nonaspirin NSAID use and *vice versa*. Tests for linear trends across the NSAID exposure categories were calculated by treating these categorical variables as ordinal variables.

In subsequent models, we adjusted for calendar time and several additional factors, including ages at menarche and menopause, mammogram in the past 3 years, self-reported heart disease, self-rated health quality, physical activity, and body mass index (BMI). The results were essentially the same and are not shown here.

We used a likelihood ratio test, comparing models with and without the interaction terms, to separately examine effect modification by age at entry (\<57 years, 57 to 60 years, 61 to 64 years, 65 to 68 years, or ≥69 years), HT use (never, estrogen only, estrogen--progestin, or other/unknown), BMI (\<25 kg/m^2^, 25 to 29 kg/m^2^, ≥30 kg/m^2^, or unknown), and smoking status (never, former, current, or unknown). In addition, we examined whether the relationship between NSAIDs and breast cancer incidence differed by ER status (positive or negative), by stage at diagnosis (*in situ*or invasive disease), and by histologic type (ductal, lobular, or mixed).

Probability values \<0.05 were considered statistically significant. All tests of statistical significance were two-tailed. Analyses were performed using SAS software release 9.1.3 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Among the 126,124 mostly white, postmenopausal women in this report, 65.6% reported ever-use of aspirin in the past 12 months. Among all women, 31.8% took aspirin less than once per week, 16.1% used aspirin one to six times per week, and 17.7% were daily aspirin users. Slightly fewer women reported ever-use of nonaspirin NSAIDs: 31.5% took nonaspirin NSAIDs less than once per week, 15.2% used nonaspirin NSAIDs one to six times per week, and 13.3% were daily nonaspirin NSAID users. Nearly 85% of women in our study reported any NSAID use within the past 12 months.

In general, aspirin and nonaspirin NSAID users shared similar characteristics (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Compared with women who did not use aspirin or nonaspirin NSAIDs in the past 12 months, women who had used aspirin or nonaspirin NSAIDs on a daily basis were more likely to be white, and to reportedly drink alcohol, smoke, use HT, have fair/poor overall health, and to report a history of hypertension. Daily aspirin users were more likely to be older and to report a history of stroke and heart disease. Daily nonaspirin NSAID users were more likely to be younger, parous, and obese (BMI ≥30 kg/m^2^), and to have a history of breast biopsy.

###### 

Distribution of select risk factors across categories of aspirin use among 126,124 women, National Institutes of Health--AARP Study

                                                                              Frequency of aspirin use in past 12 months                                                   
  --------------------------------------------------------------------------- -------------------------------------------- ------ -------- ------ -------- ------ -------- ------
  Age at second questionnaire                                                                                                                                              
   \<57 years                                                                 8,178                                        19.0   8,629    21.7   4,029    20.1   2,936    13.3
   57--60 years                                                               8,317                                        19.4   8,211    20.6   4,022    20.1   3,566    16.2
   61--64 years                                                               9,750                                        22.7   9,025    22.7   4,644    23.2   5,132    23.2
   65--68 years                                                               11,085                                       25.8   9,459    23.8   4,881    24.3   6,607    29.9
   69+ years                                                                  5,630                                        13.1   4,457    11.2   2,481    12.4   3,839    17.4
  Race/ethnicity                                                                                                                                                           
   Caucasian/non-Hispanic white                                               38,339                                       89.2   36,340   91.4   18,561   92.5   20,381   92.3
   Other/unknown                                                              4,621                                        10.8   3,441    8.6    1,496    7.5    1,699    7.7
  Education                                                                                                                                                                
   \<High school/high school grad                                             13,537                                       32.5   10,675   27.5   5,769    29.6   6,857    32.0
   Post-high school+                                                          28,171                                       67.5   28,110   72.5   13,696   70.4   14,554   68.0
  Body mass index at baseline                                                                                                                                              
   \<25 kg/m^2^                                                               18,461                                       44.7   18,855   48.9   9,040    46.6   8,718    40.8
   25--30 kg/m^2^                                                             13,144                                       31.8   12,331   32.0   6,407    33.0   7,290    34.2
   30+ kg/m^2^                                                                9,719                                        23.5   7,342    19.1   3,965    20.4   5,335    25.0
  Smoking                                                                                                                                                                  
   Never                                                                      19,321                                       46.3   18,123   47.0   8,996    46.4   8,984    42.1
   Former                                                                     16,758                                       40.2   15,314   39.7   7,735    39.9   9,184    43.0
   Current                                                                    5,630                                        13.5   5,137    13.3   2,656    13.7   3,193    14.9
  Alcoholic drinks                                                                                                                                                         
   0 drinks per day                                                           14,515                                       33.8   9,136    23.0   4,784    23.9   7,009    31.7
   \<1 drink per day                                                          23,322                                       54.3   24,771   62.3   12,299   61.3   12,111   54.9
   1--3 drinks per day                                                        4,037                                        9.4    4,727    11.9   2,382    11.9   2,297    10.4
   3+ drinks per day                                                          1,086                                        2.5    1,147    2.9    592      3.0    663      3.0
  Self-reported general health                                                                                                                                             
   Excellent/very good/good                                                   36,189                                       85.6   36,638   93.3   17,869   90.4   17,868   82.4
   Fair/poor                                                                  6,094                                        14.4   2,639    6.7    1,891    9.6    3,814    17.6
  Stroke                                                                                                                                                                   
   No                                                                         42,293                                       98.4   39,557   99.4   19,844   98.9   21,112   95.6
   Yes                                                                        667                                          1.6    224      0.6    213      1.1    968      4.4
  Heart disease                                                                                                                                                            
   No                                                                         39,820                                       92.7   38,292   96.3   18,924   94.4   17,561   79.5
   Yes                                                                        3,140                                        7.3    1,489    3.7    1,133    5.6    4,519    20.5
  High blood pressure                                                                                                                                                      
   No                                                                         24,240                                       60.2   25,179   67.7   11,484   61.5   9,502    46.1
   Yes                                                                        16,001                                       39.8   11,997   32.3   7,192    38.5   11,117   53.9
  Mammogram in past 3 years                                                                                                                                                
   Once or less                                                               13,226                                       31.0   12,161   30.8   6,043    30.4   6,496    29.8
   Yes, more than once                                                        29,408                                       69.0   27,298   69.2   13,827   69.6   15,327   70.2
  Age at menarche                                                                                                                                                          
   \<13 years                                                                 21,222                                       49.8   18,850   47.8   9,679    48.7   11,036   50.4
   13--14 years                                                               17,452                                       41.0   17,101   43.4   8,407    42.3   8,859    40.5
   15+ years                                                                  3,909                                        9.2    3,492    8.9    1,792    9.0    1,981    9.1
  Parity                                                                                                                                                                   
   Nulliparous                                                                6,253                                        14.8   5,996    15.3   2,808    14.2   3,089    14.3
   One                                                                        4,459                                        10.6   4,056    10.4   2,009    10.2   2,172    10.0
   Two                                                                        11,052                                       26.2   10,488   26.8   5,290    26.8   5,406    25.0
   Three or more                                                              20,431                                       48.4   18,578   47.5   9,608    48.7   10,987   50.7
  Age at first live birth                                                                                                                                                  
   Nulliparous                                                                6,253                                        14.8   5,996    15.3   2,808    14.2   3,089    14.2
   \<20 years                                                                 7,385                                        17.4   6,016    15.3   3,319    16.8   3,895    17.9
   20--24 years                                                               18,472                                       43.6   17,112   43.6   8,861    44.9   9,800    45.1
   25--29 years                                                               7,636                                        18.0   7,582    19.3   3,632    18.4   3,739    17.2
   30+ years                                                                  2,575                                        6.1    2,499    6.4    1,129    5.7    1,191    5.5
  Age at menopause                                                                                                                                                         
   Premenopausal                                                              1,462                                        3.4    1,738    4.4    742      3.7    445      2.0
   \<45 years                                                                 2,834                                        6.6    2,429    6.1    1,266    6.3    1,593    7.2
   45--49 years                                                               6,543                                        15.2   6,316    15.9   2,997    14.9   3,358    15.2
   50--54 years                                                               11,362                                       26.4   11,870   29.8   5,415    27.0   5,732    26.0
   55+ years                                                                  2,650                                        6.2    2,555    6.4    1,218    6.1    1,284    5.8
   Surgical menopause                                                         16,770                                       39.0   13,577   34.1   7,754    38.7   8,975    40.6
   Postmenopausal, age unknown                                                1,339                                        3.1    1,296    3.3    665      3.3    693      3.1
  Hormone therapy formulation                                                                                                                                              
   Never used                                                                 17,328                                       42.4   15,676   41.2   7,201    37.6   8,371    39.8
   Estrogen therapy only                                                      11,901                                       29.1   10,157   26.7   5,844    30.5   6,724    32.0
   Estrogen--progestin therapy                                                11,681                                       28.6   12,196   32.1   6,100    31.9   5,945    28.3
  Moderate/vigorous physical activity during past 10 years                                                                                                                 
   Never                                                                      1,801                                        4.3    1,033    2.6    545      2.8    878      4.0
   Rarely                                                                     4,911                                        11.6   4,012    10.2   1,986    10.1   2,539    11.7
   \<1 hour/week                                                              4,473                                        10.6   4,102    10.5   2,107    10.7   2,347    10.8
   1--3 hours/week                                                            10,495                                       24.9   10,085   25.7   5,240    26.6   5,457    25.1
   4--7 hours/week                                                            10,379                                       24.6   10,438   26.6   5,311    26.9   5,371    24.7
   \>7 hours/week                                                             10,100                                       24.0   9,548    24.3   4,546    23.0   5,122    23.6
  Number breast biopsies                                                                                                                                                   
   None                                                                       32,240                                       75.8   30,183   76.6   14,985   75.4   16,551   75.8
   One                                                                        6,819                                        16.0   6,175    15.7   3,217    16.2   3,428    15.7
   Two                                                                        1,904                                        4.5    1,666    4.2    926      4.7    997      4.6
   Three or more                                                              1,581                                        3.7    1,360    3.5    737      3.7    863      4.0
  Family history of breast cancer in first degree relative (male or female)                                                                                                
   No                                                                         29,536                                       83.5   27,782   83.8   13,814   83.6   14,930   83.4
   Yes                                                                        5,838                                        16.5   5,356    16.2   2,708    16.4   2,978    16.6

^a^Missing values were excluded from percentage calculations.

###### 

Distribution of select risk factors across categories of nonaspirin nonsteroidal anti-inflammatory drug (NSAID) use among 126,124 women, National Institutes of Health--AARP Study

                                                                              Frequency of nonaspirin NSAID use in past 12 months                                                   
  --------------------------------------------------------------------------- ----------------------------------------------------- ------ -------- ------ -------- ------ -------- ------
  Age at second questionnaire                                                                                                                                                       
   \<57 years                                                                 7,112                                                 14.3   9,185    23.4   4,563    24.0   2,955    17.9
   57--60 years                                                               8,605                                                 17.3   8,288    21.1   4,171    21.9   3,052    18.4
   61--64 years                                                               11,482                                                23.0   8,854    22.5   4,278    22.5   3,876    23.4
   65--68 years                                                               14,666                                                29.4   8,841    22.5   4,039    21.2   4,399    26.6
   69+ years                                                                  7,962                                                 16.0   4,136    10.5   1,962    10.3   2,263    13.7
  Race/ethnicity                                                                                                                                                                    
   Caucasian/non-Hispanic white                                               44,909                                                90.1   35,940   91.4   17,537   92.2   15,103   91.3
   Other/unknown                                                              4,918                                                 9.9    3,364    8.6    1,476    7.8    1,442    8.7
  Education                                                                                                                                                                         
   \<High school/high school grad                                             16,007                                                33.1   10,402   27.1   5,595    30.3   4,734    29.5
   Post-high school+                                                          32,364                                                66.9   27,959   72.9   12,851   69.7   11,312   70.5
  Body mass index at baseline                                                                                                                                                       
   \<25 kg/m^2^                                                               23,279                                                48.6   18,527   48.6   7,800    42.4   5,418    33.9
   25--30 kg/m^2^                                                             15,189                                                31.7   12,423   32.6   6,194    33.7   5,296    33.2
   30+ kg/m^2^                                                                9,464                                                 19.7   7,193    18.9   4,413    24.0   5,254    32.9
  Smoking                                                                                                                                                                           
   Never                                                                      22,702                                                47.0   17,354   45.5   8,254    44.8   7,062    44.0
   Former                                                                     18,554                                                38.4   15,751   41.3   7,708    41.9   6,942    43.2
   Current                                                                    7,025                                                 14.6   5,023    13.2   2,453    13.3   2,050    12.8
  Alcoholic drinks                                                                                                                                                                  
   0 drinks per day                                                           16,225                                                32.6   9,230    23.5   4,728    24.9   5,121    31.0
   \<1 drink per day                                                          27,087                                                54.4   24,388   62.0   11,660   61.3   9,312    56.3
   1--3 drinks per day                                                        5,108                                                 10.3   4,570    11.6   2,153    11.3   1,616    9.8
   3+ drinks per day                                                          1,407                                                 2.8    1,116    2.8    472      2.5    496      3.0
  Self-reported general health                                                                                                                                                      
   Excellent/very good/good                                                   42,891                                                87.5   35,824   92.4   16,655   88.8   13,073   80.5
   Fair/poor                                                                  6,142                                                 12.5   2,966    7.6    2,106    11.2   3,176    19.5
  Stroke                                                                                                                                                                            
   No                                                                         48,762                                                97.9   38,882   98.9   18,760   98.7   16,223   98.1
   Yes                                                                        1,065                                                 2.1    422      1.1    253      1.3    322      1.9
  Heart disease                                                                                                                                                                     
   No                                                                         44,964                                                90.2   36,916   93.9   17,658   92.9   14,936   90.3
   Yes                                                                        4,863                                                 9.8    2,388    6.1    1,355    7.1    1,609    9.7
  High blood pressure                                                                                                                                                               
   No                                                                         27,666                                                59.6   23,960   65.1   10,656   60.1   8,036    51.7
   Yes                                                                        18,783                                                40.4   12,847   34.9   7,080    39.9   7,508    48.3
  Mammogram in past 3 years                                                                                                                                                         
   Once or less                                                               17,403                                                35.3   10,768   27.6   5,095    27.0   4,509    27.5
   Yes, more than once                                                        31,949                                                64.7   28,229   72.4   13,749   73.0   11,904   72.5
  Age at menarche                                                                                                                                                                   
   \<13 years                                                                 23,714                                                48.1   18,717   48.0   9,436    50.0   8,816    53.7
   13--14 years                                                               21,018                                                42.6   16,749   43.0   7,752    41.1   6,269    38.2
   15+ years                                                                  4,604                                                 9.3    3,516    9.0    1,685    8.9    1,336    8.1
  Parity                                                                                                                                                                            
   Nulliparous                                                                8,010                                                 16.4   5,540    14.3   2,375    12.7   2,212    13.6
   One                                                                        5,330                                                 10.9   4,022    10.4   1,794    9.6    1,546    9.5
   Two                                                                        12,441                                                25.5   10,535   27.2   5,125    27.3   4,095    25.2
   Three or more                                                              23,059                                                47.2   18,566   48.0   9,445    50.4   8,418    51.7
  Age at first live birth                                                                                                                                                           
   Nulliparous                                                                8,010                                                 16.4   5,540    14.3   2,375    12.6   2,212    13.6
   \<20 years                                                                 7,690                                                 15.7   6,056    15.6   3,559    19.0   3,229    19.8
   20--24 years                                                               21,059                                                43.0   17,194   44.4   8,585    45.7   7,350    45.1
   25--29 years                                                               9,058                                                 18.5   7,520    19.4   3,310    17.6   2,676    16.4
   30+ years                                                                  3,153                                                 6.4    2,439    6.3    948      5.0    844      5.2
  Age at menopause                                                                                                                                                                  
   Premenopausal                                                              1,145                                                 2.3    1,864    4.7    886      4.7    487      2.9
   \<45 years                                                                 3,654                                                 7.3    2,377    6.0    1,063    5.6    995      6.0
   45--49 years                                                               8,216                                                 16.5   5,941    15.1   2,732    14.4   2,288    13.8
   50--54 years                                                               14,355                                                28.8   11,383   29.0   4,705    24.7   3,895    23.5
   55+ years                                                                  3,209                                                 6.4    2,519    6.4    1,019    5.4    945      5.7
   Surgical menopause                                                         17,713                                                35.5   13,938   35.5   7,962    41.9   7,430    44.9
  Postmenopausal, age unknown                                                 1,535                                                 3.1    1,282    3.3    646      3.4    505      3.1
  Hormone therapy formulation                                                                                                                                                       
   Never used                                                                 23,083                                                48.6   14,199   37.8   5,961    32.9   5,179    32.8
   Estrogen therapy only                                                      12,664                                                26.7   10,499   27.9   5,910    32.7   5,522    35.0
   Estrogen--progestin therapy                                                11,762                                                24.8   12,876   34.3   6,224    34.4   5,072    32.2
  Moderate/vigorous physical activity during past 10 years                                                                                                                          
   Never                                                                      1,922                                                 3.9    1,004    2.6    551      2.9    749      4.6
   Rarely                                                                     5,434                                                 11.1   3,953    10.2   1,993    10.6   2,032    12.5
   \<1 hour/week                                                              5,034                                                 10.3   4,196    10.8   1,980    10.6   1,815    11.2
   1--3 hours/week                                                            12,127                                                24.8   10,252   26.4   4,815    25.7   4,091    25.2
   4--7 hours/week                                                            12,378                                                25.3   10,169   26.2   4,981    26.6   3,924    24.1
   \>7 hours/week                                                             12,017                                                24.6   9,234    23.8   4,397    23.5   3,642    22.4
  Number breast biopsies                                                                                                                                                            
   None                                                                       37,903                                                76.9   29,547   75.9   14,113   74.9   12,243   74.7
   One                                                                        7,549                                                 15.3   6,236    16.0   3,114    16.5   2,727    16.6
   Two                                                                        2,042                                                 4.1    1,779    4.6    884      4.7    768      4.7
   Three or more                                                              1,793                                                 3.6    1,373    3.5    743      3.9    652      4.0
  Family history of breast cancer in first degree relative (male or female)                                                                                                         
   No                                                                         33,976                                                83.6   27,478   83.7   13,197   83.8   11,295   82.8
   Yes                                                                        6,643                                                 16.4   5,346    16.3   2,554    16.2   2,347    17.2

^a^Missing values were excluded from percentage calculations.

The 126,124 women accrued 836,863 person-years during an average follow-up of 3.43 years for cases (range, 1 day to 7.13 years) and of 6.75 years for noncases (range, 1 day to 7.17 years). The mean (standard deviation) ages for entry and exit were 63.1 (5.2) years and 66.5 (5.6) years for cases and were 62.6 (5.4) years and 69.3 (5.4) years for noncases, respectively. Breast cancer risk factors in this population were generally consistent with established associations with age, BMI, ages at menarche, first birth and menopause, parity, estrogen--progestin therapy use, number of breast biopsies, and family history of breast cancer.

Because NSAID exposure was collected on the second questionnaire, and the response rate for this questionnaire was \~60%, we also examined the association between breast cancer risk factors captured on the first questionnaire and breast cancer risk among the entire cohort. The associations between risk factors and breast cancer in the entire cohort were comparable with those observed in the subcohort of respondents to the second questionnaire (data not shown).

Nonsteroidal anti-inflammatory drug use and breast cancer
---------------------------------------------------------

In multivariate proportional hazards models, there was no statistically significant association between ever-use of NSAIDs in the past 12 months and total breast cancer (Table [3](#T3){ref-type="table"}). Compared with nonusers, the relative risks (RRs) of breast cancer associated with ever-use of aspirin only, with nonaspirin NSAIDs only, or with both were 0.97 (95% CI = 0.88 to 1.07), 1.01 (95% CI = 0.92 to 1.12), and 0.95 (95% CI = 0.87 to 1.04), respectively. We tested associations by frequency of NSAID type. The risk of total breast cancer was slightly reduced with daily use (versus nonuse) of aspirin (RR = 0.93, 95% CI = 0.85 to 1.01), albeit statistically nonsignificantly (for trend *P*= 0.08). Compared with nonuse, daily use of nonaspirin NSAIDs was not associated with breast cancer risk (RR = 0.96, 95% CI = 0.87 to 1.05). The association between NSAID use and breast cancer risk was not modified by age, HT use, BMI, or smoking (data not shown).

###### 

Association between nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer among 126,124 women, National Institutes of Health--AARP Study

                             Number of cancers   Person-years   Relative risk^a^   95% confidence interval   *P*value for trend
  -------------------------- ------------------- -------------- ------------------ ------------------------- --------------------
  NSAID use                                                                                                  
   Never                     667                 124,265        1.00 (referent)                              n/a
   Aspirin only              1,085               203,145        0.97               0.88 to 1.07              
   Non-aspirin NSAID only    874                 157,017        1.01               0.92 to 1.12              
   Both                      1,781               334,792        0.95               0.87 to 1.04              
  Aspirin use^b^                                                                                             
   Never                     1,556               284,342        1.00 (referent)                              0.08
   \<1/week                  1,405               265,676        0.95               0.89 to 1.03              
   1--6/week                 716                 133,331        0.95               0.87 to 1.04              
   1+/day                    774                 145,317        0.93               0.85 to 1.01              
  Non-aspirin NSAID use^b^                                                                                   
   Never                     1,764               329,944        1.00 (referent)                              0.58
   \<1/week                  1,415               262,000        1.00               0.93 to 1.07              
   1--6/week                 693                 126,373        1.02               0.93 to 1.11              
   1+/day                    585                 109,098        0.96               0.87 to 1.05              

^a^Adjusted for age (continuous), race, age at first birth, hormone therapy use, number of breast biopsies, alcohol intake, history of hypertension, and family history of breast cancer in first-degree relative.

^b^These models also include terms for frequency of use of opposite NSAID type.

Several differences emerged in analyses stratified by ER status and stage (Tables [4](#T4){ref-type="table"} to [6](#T6){ref-type="table"}). The RR of ER-positive breast cancer was reduced with daily aspirin use (RR = 0.84, 95% CI = 0.71 to 0.98), and no association was observed with daily use of nonaspirin NSAIDs (RR = 0.98, 95% CI = 0.83 to 1.16) (Table [4](#T4){ref-type="table"}). In contrast, ER-negative breast cancer was not associated with daily aspirin or nonaspirin NSAID use. The inverse relationships with aspirin use were weak for invasive breast cancer but were stronger for *in situ*disease (Table [5](#T5){ref-type="table"}), and these differences were not entirely explained by mammographic screening: in analyses restricted to women who reported having two or more mammograms in the past three years, the risks associated with daily aspirin use for invasive and *in situ*breast cancers were 0.95 (95% CI = 0.85 to 1.06) and 0.75 (95% CI = 0.59 to 0.95), respectively (Table [6](#T6){ref-type="table"}). There was little variation in risks for nonaspirin NSAIDs according to ER status and stage. Risk relationships for aspirin and nonaspirin NSAIDs did not vary by histologic subtype for invasive cancers (data not shown).

###### 

Association between nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer by estrogen receptor status, National Institutes of Health--AARP Study

                            Estrogen receptor-positive   Estrogen receptor-negative                                                                                            
  ------------------------- ---------------------------- ---------------------------- ----------------- -------------- ------ ----- --------- ----------------- -------------- ------
  Aspirin use^b^                                                                                                                                                               
   Never                    493                          280,706                      1.00 (referent)                  0.06   88    279,308   1.00 (referent)                  0.54
   \<1/week                 464                          262,491                      0.98              0.86 to 1.11          93    261,137   1.09              0.81 to 1.47   
   1--6/week                243                          131,724                      1.00              0.86 to 1.17          42    131,022   1.01              0.70 to 1.47   
   1+/day                   223                          143,476                      0.84              0.71 to 0.98          52    142,852   1.14              0.81 to 1.62   
  Nonaspirin NSAID use^b^                                                                                                                                                      
   Never                    541                          325,816                      1.00 (referent)                  0.86   108   324,250   1.00 (referent)                  0.64
   \<1/week                 466                          258,767                      1.04              0.92 to 1.18          96    257,460   1.08              0.81 to 1.43   
   1--6/week                230                          124,804                      1.07              0.92 to 1.26          36    124,115   0.85              0.58 to 1.25   
   1+/day                   186                          107,763                      0.98              0.83 to 1.16          36    107,241   0.97              0.66 to 1.42   

The threshold for a positive estrogen receptor was ≥10 fmol receptor/mg total protein. ^a^Adjusted for age (continuous), race, age at first birth, hormone therapy use, number of breast biopsies, alcohol intake, history of hypertension, and family history of breast cancer in first-degree relative. ^b^These models also include terms for frequency of use of opposite NSAID type.

###### 

Association between nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer according to stage, National Institutes of Health--AARP Study

                             *In situ*breast cancer   Invasive breast cancer                                                                                              
  -------------------------- ------------------------ ------------------------ ----------------- -------------- ------ ------- --------- ----------------- -------------- ------
  Aspirin use^b^                                                                                                                                                          
   Never                     298                      280,077                  1.00 (referent)                  0.02   1,254   283,247   1.00 (referent)                  0.37
   \<1/week                  233                      261,641                  0.80              0.67 to 0.96          1,166   264,821   0.99              0.91 to 1.07   
   1--6/week                 124                      131,305                  0.85              0.69 to 1.05          589     132,899   0.98              0.88 to 1.08   
   1+/day                    122                      143,137                  0.78              0.63 to 0.96          648     144,854   0.96              0.87 to 1.06   
  Non-aspirin NSAID use^b^                                                                                                                                                
   Never                     292                      324,890                  1.00 (referent)                  0.45   1,463   328,884   1.00 (referent)                  0.88
   \<1/week                  269                      258,097                  1.14              0.96 to 1.35          1,140   261,013   0.97              0.90 to 1.05   
   1--6/week                 122                      124,433                  1.06              0.85 to 1.31          569     125,934   1.01              0.92 to 1.12   
   1+/day                    91                       107,466                  0.87              0.69 to 1.10          494     108,757   0.98              0.89 to 1.09   

^a^Adjusted for age (continuous), race, age at first birth, hormone therapy use, number of breast biopsies, alcohol intake, history of hypertension, and family history of breast cancer in first-degree relative.

^b^These models also include terms for frequency of use of opposite NSAID type.

###### 

Association between nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer according to stage among screened women, National Institutes of Health--AARP Study

                             *In situ*breast cancer   Invasive breast cancer                                                                                            
  -------------------------- ------------------------ ------------------------ ----------------- -------------- ------ ----- --------- ----------------- -------------- ------
  Aspirin use^b^                                                                                                                                                        
   Never                     241                      192,125                  1.00 (referent)                  0.02   916   194,396   1.00 (referent)                  0.15
   \<1/week                  180                      179,747                  0.77              0.63 to 0.93          847   181,986   0.98              0.89 to 1.07   
   1--6/week                 97                       90,680                   0.82              0.65 to 1.05          402   91,715    0.90              0.80 to 1.01   
   1+/day                    96                       99,793                   0.75              0.59 to 0.95          476   101,064   0.95              0.85 to 1.06   
  Non-aspirin NSAID use^b^                                                                                                                                              
   Never                     218                      209,044                  1.00 (referent)                  0.50   982   211,655   1.00 (referent)                  0.62
   \<1/week                  222                      185,624                  1.16              0.95 to 1.40          852   187,741   0.98              0.89 to 1.07   
   1--6/week                 97                       90,035                   1.03              0.81 to 1.31          428   91,161    1.03              0.92 to 1.16   
   1+/day                    76                       77,462                   0.89              0.69 to 1.16          384   78,439    1.02              0.91 to 1.15   

This analysis was restricted to women who reported ≥2 mammograms in the past 3 years. ^a^Adjusted for age (continuous), race, age at first birth, hormone therapy use, number of breast biopsies, alcohol intake, history of hypertension, and family history of breast cancer in first-degree relative. ^b^These models also include terms for frequency of use of opposite NSAID type.

Discussion
==========

In the present large prospective study, we found that NSAID use was unrelated to risk of total breast cancer. Daily aspirin, but not nonaspirin NSAID, use was associated with a modest 16% reduction in ER-positive breast cancer. We did not observe an association between NSAID use and ER-negative breast cancer.

Our null findings for total breast cancer are consistent with those reported by eight prospective studies \[[@B8]-[@B15]\] and one randomized clinical trial \[[@B25]\] that examined aspirin and/or nonaspirin NSAID use. Our results differ, however, from those from seven prospective studies \[[@B17],[@B19]-[@B24]\] and 12 case--control studies \[[@B1]-[@B3],[@B30]-[@B33],[@B40]-[@B44]\], most of which have reported reduced risks of breast cancer associated with NSAID use. The reasons for these differing results are unclear, but associations may be limited to certain subtypes of breast cancer. Differences in NSAID exposure assessment across studies may also account for inconsistent results.

The frequency of aspirin and nonaspirin use in the NIH--AARP Diet and Health Study is consistent with that reported in other US cohorts of women \[[@B21],[@B45]\], and the proportion of women in this study using any NSAID is only slightly higher than that reported among females ages 45 to 75+ years in the third National Health and Nutrition Examination Survey -- 71.5% to 80.4% of whom reported any nonprescription analgesic in the past month \[[@B46]\]. Our study lacked information, however, on the duration, dose, indication, or prescription NSAID use. Because we only measured recent NSAID use in the year prior to the 1996 to 1997 questionnaire and followed women through 2003, the null findings we observed for NSAIDs may differ from what might be observed with long-term cumulative exposure. Indeed, several cohort studies have shown that long-term NSAID use is required for an observed chemopreventive effect on breast cancer \[[@B22],[@B23]\]. Furthermore, if there were individuals in our referent category who were past users or prescription NSAID users, results could be biased toward the null.

In addition, we were unable to separate low-dose from regular-dose aspirin use; results from the Women\'s Health Study randomized trial \[[@B25]\], a study conducted using an insurance database \[[@B2]\], and laboratory evidence \[[@B27]\] suggest that doses higher than the 80 mg aspirin per day typically recommended for cardiovascular therapy may be required to permanently inactivate COX-2. If low-dose aspirin users were included in our exposed group, thereby diluting any effect associated with regular-dose aspirin use, the results would be biased toward the null. Although we did not collect information on indication for use, it is likely that some daily users were taking aspirin for heart disease prevention given that daily users more frequently reported history of heart disease. To address the concern that women using NSAIDS for cardioprotection may be under closer medical supervision and/or may be more health conscious, we additionally controlled for self-reported heart disease, self-rated health quality, and mammographic screening -- and the results remained unchanged.

Despite these limitations, the NIH--AARP Diet and Health Study is the one of largest cohorts to date to have evaluated the association between NSAID type and breast cancer risk by tumor characteristics, including ER status. The reduced risk of ER-positive breast cancer we observed with daily aspirin use is consistent with the mechanism of action of aspirin (but not nonaspirin NSAIDs), which permanently inactivates COX-2 \[[@B29]\], potentially reducing breast cancer risk via multiple pathways, including suppression of estrogen synthesis by decreased aromatase activity \[[@B28]\]. In addition, our results are in agreement with findings from the Long Island Breast Cancer Prevention Project, a population-based case--control study that reported in 2004 an inverse association with aspirin that was significantly greater for HR-positive breast cancer than for HR-negative breast cancer \[[@B30]\]. Since then, two case--control studies \[[@B3],[@B31]\] and three prospective cohort studies \[[@B16],[@B17],[@B24]\] have separately investigated the association for aspirin, with three of the five studies suggesting some protection against HR-positive breast cancer with aspirin use \[[@B3],[@B16],[@B31]\].

A US hospital-based study -- the Case--Control Surveillance Study -- reported a 26% nonsignificant reduction (95% CI = 0.44 to 1.26) in HR-positive breast cancer associated with regular (versus \<4 times/week) aspirin use \[[@B31]\]. More recently, a Canadian population-based case--control study found a 31% reduction (95% CI = 0.56 to 0.86) in ER-positive/PR-positive breast cancer associated with daily (versus \<daily) aspirin use \[[@B3]\]. The California Teachers Study followed 114,460 women aged 22 to 85 years for 6 years and found that long-term daily (versus \<once/week) aspirin use was associated with a statistically nonsignificant decreased risk of ER-positive/PR-positive breast cancer (RR = 0.80, 95% CI = 0.62 to 1.03) \[[@B16]\]. In contrast, the Multiethnic Cohort Study and the Danish Diet, Cancer and Health Cohort Study found no protective effect of aspirin use for HR-positive or HR-negative breast cancer \[[@B17],[@B24]\]. Finally, the Women\'s Health Study randomized clinical trial did not observe any significant patterns of risk by HR status with low-dose aspirin use \[[@B25]\]. Therefore, while our findings, along with several others, suggest at least some reduction in ER-positive breast cancer associated with aspirin use, the evidence is not conclusive and additional prospective studies with detailed exposure data on the dose, frequency, duration, and indication are needed.

We found stronger inverse associations with *in situ*breast cancer than invasive breast cancer. Among the few prior studies that have reported results separately for *in situ*breast cancer and invasive breast cancer, two case--control studies reported decreased risks of both *in situ*and invasive breast cancers associated with aspirin \[[@B30]\] and with any NSAID use \[[@B32]\], but the findings for *in situ*breast cancer were not statistically significant in either study. The Iowa Women\'s Health cohort study reported a reduction in breast cancer risk with increased frequency of aspirin, but not with nonaspirin NSAIDs, for both *in situ*and invasive disease \[[@B21]\]. Both *in situ*and invasive breast tumors express COX-2 \[[@B47]\], suggesting that upregulation of COX-2 may be an early event in carcinogenesis. Higher rates of COX-2 expression in *in situ*compared with invasive tumors have led investigators to suggest that the potential therapeutic impact of COX-2 inhibition may be more relevant for *in situ*breast cancer than invasive breast cancer (reviewed in \[[@B48]\]). The inverse association for *in situ*breast cancer associated with aspirin use in the present study may therefore be biologically plausible and warrants further investigation.

We observed no variation in risk with HT, smoking status, or BMI, and our findings are generally consistent with previous investigations. For the most part, tests for interactions between HT and NSAID use have been statistically nonsignificant across case--control studies \[[@B30],[@B33]\] and cohort studies \[[@B13],[@B17],[@B22],[@B24],[@B25]\]; however, two cohort studies have suggested the protective effect of NSAIDs may be attenuated among HT users \[[@B18],[@B20]\]. In line with data suggesting that proinflammatory tobacco carcinogens may alter the effectiveness of chemopreventive agents \[[@B49]\], the Women\'s Health Study found that low-dose aspirin use was protective among former smokers but was associated with an increased risk among never smokers (for interaction *P*= 0.09) \[[@B25]\]. We, along with a Canadian population-based case--control study, however, did not observe effect modification by smoking \[[@B3]\]. Consistent with our findings, two case--control studies \[[@B32],[@B33]\] and seven prospective studies \[[@B13],[@B17],[@B18],[@B20],[@B22],[@B24],[@B25]\] have reported no significant interactions between BMI and NSAID use with respect to breast cancer risk.

Conclusion
==========

In summary, our results do not support an important influence of NSAIDs on total breast cancer risk. Daily aspirin use, however, appeared to offer some protection for ER-positive breast cancer in this population. In addition, our findings suggest that the associations for aspirin use may vary by tumor stage. Our results provide support for further evaluating relationships in prospective studies with well-defined measures of NSAID use by NSAID type, by breast cancer stage, and by ER status.
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